Advanced Nanovehicles-Enabled Delivery Systems of Epigallocatechin Gallate for Cancer Therapy

31Citations
Citations of this article
46Readers
Mendeley users who have this article in their library.

Abstract

Epigallocatechin gallate (EGCG) is the most abundant polyphenolic constituent derived from green tea extract, which has demonstrated versatile bioactivities in combating cardiovascular diseases, neurodegenerative diseases, diabetes, and cancer. In light of its anticancer activity, increasing attention has been paid to developing potent strategies involving EGCG in cancer chemotherapy. However, the poor bioavailability and stability of EGCG limits its effectiveness and practicality in real biomedical applications. To overcome this drawback, nanotechnology-facilitated drug delivery systems have been introduced and intensively explored to enhance the bioavailability and therapeutic efficacy of EGCG in cancer treatments and interventions. This review briefly discusses the anticancer mechanisms of EGCG, and then summarizes recent advances in engineering nanovehicles for encapsulating and delivering EGCG toward cancer therapy. In addition, we also highlight successful integrations of EGCG delivery with other chemotherapies, gene therapies, and phototherapies in one nanostructured entity for a combination therapy of cancers. To conclude, the current challenges and future prospects of the nanovehicle-based transportation systems of EGCG for cancer therapy are also discussed.

Cite

CITATION STYLE

APA

Li, K., Teng, C., & Min, Q. (2020, October 23). Advanced Nanovehicles-Enabled Delivery Systems of Epigallocatechin Gallate for Cancer Therapy. Frontiers in Chemistry. Frontiers Media S.A. https://doi.org/10.3389/fchem.2020.573297

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free